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outcomes. Further analysis should be performed in registries. Thus,
the JCARE-CARD suggests how important epidemiological study is
for better practical guidelines, although these four ﬁndings are just
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Hospitalization for heart failure (HHF) is a critical problem in
apan as well as Western countries. A recent statistical analysis
evealed that the number of Japanese outpatients with left ven-
ricular dysfunction was 979,000 in 2005. It will increase by 90,000
very 5 years, reaching 1.3 million by 2030 [1]. Based on this anal-
sis, the number of HHF must be increased markedly and cause
eﬁnite ﬁnancial burden in Japan. In the USA, HHF in patients over
he age of 65 years results in 6.5 million hospital days annually
2]. Furthermore, unplanned readmissions cause ﬁnancial burden
nd cost Medicare $17.4 billion annually [3]. Thus, fundamental
nformation regarding HHF is essential to improve managements
f HHF, but it is lacking in Japan. From this viewpoint, the report
rom the JCARE-CARD [4] is valuable as the ﬁrst step to improve
he management of HHF in Japan. Worsening chronic HF result-
ng in hospitalization may  be associated with cardiac and renal
njuries that contribute to progression of HF and cause high re-
dmission rates. In terms of this concept, recently the word “HHF”
as been used, deﬁned as new-onset or worsening signs and symp-
oms of HF that require urgent therapy and result in hospitalization
5].
One of the most important aims of an epidemiological study for
HF is to validate the guideline for improving the managements
f HHF in each country or region. Hamaguchi et al. have provided
mportant information regarding the management of HHF patients
ue to worsening chronic HF, i.e. (1) only half of patients were
reated with angiotensin-converting enzyme inhibitors (ACEIs) or
ngiotensin II receptor blockers (ARBs) before hospitalization; (2)
eta-blocker utilization was observed in only 22% patients with
hronic HF before hospitalization; (3) ARB use before admission
as signiﬁcantly associated with decreased in-hospital mortality
4]; and (4) there was markedly long length of stay (LOS) in wors-
ning HF.
Lower rates of patients receiving ACEIs or ARBs for chronic HF
efore admission were critical issues in real-world management for
econdary prevention of HHF, suggesting that the standard ther-
pies recommended by the guidelines should be complied with
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Open accessmore except where contra-indicated, although prescriptions for
these agents at discharge were much better. However, the anal-
ysis from the JCARE-CARD showed that ARB use before admission
was related to lower in-hospital mortality, which supported partly
ARB use for HF in Japan. Needless to say, further prospective study
should be performed to clarify whether ARB use is better than that
of ACE inhibitors for HF in Japan. Lower rate of beta-blocker uti-
lization was demonstrated in the JCARE-CARD, which was  also not
consistent with the recommendations of the guidelines. Another
critical issue was  long LOS in Japan. The JCARE-CARD demonstrated
markedly long LOS, i.e. median 15 days, in worsening HF in Japan.
Furthermore, the analysis revealed that LOS was not associated
with all-cause mortality after discharge. Another epidemiological
study of acute HF including de novo HF, the ATTEND registry, also
showed that median LOS, 21 days, was markedly longer LOS  than
that of Western countries [6]. From these ﬁndings, appropriate LOS
in terms of clinical and economic beneﬁts should be discussed and
improved in Japan. Sub-analysis from the ATTEND registry revealed
the frequency of sudden death was  much higher during the ﬁrst 14
days, especially 7 days, after admission than at any other time, with
71.4% of sudden deaths occurring during this period [7], suggest-
ing that the LOS in the USA, 4 days, might be too short for betterFeedback to
the guideline
Fig. 1. Periodic registries are necessary to verify the practical guidelines. This loop
can improve the outcome of the patients with hospitalization for heart failure.
 under CC BY-NC-ND license.
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art of a lot of ﬁndings revealed in real-world management for
F.
The guidelines are not only summary of evidence but also offer
ractical guidance to improve quality of life and outcomes for HF
atients. Therefore, they should be re-evaluated and modiﬁed as
hown in Fig. 1. However, veriﬁcation of the HF guideline by an
pidemiological study has never been performed in Japan. From
his viewpoint, the JCARE-CARD and the ATTEND registry are clini-
ally meaningful for the next HF guidelines. Periodic veriﬁcation of
he guidelines is also important (Fig. 1). In Korea, periodic epidemi-
logical studies, KorHF registries, have been established and were
xpected to improve adherence of doctors to standardized therapy
nd indicate improved therapeutic strategies for HF [8]. Hopefully,
eriodic HF registries should be established under the direction of
he Ministry of Health, Labour and Welfare, which will be able to
mprove HF management in Japan and also reduce ﬁnancial burden
n the cardiovascular ﬁeld.
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